Alyftrek Expansion Drives Vertex's International Growth

Dow Jones05:59

Vertex Pharmaceuticals secures reimbursement for cystic fibrosis therapy Alyftrek in seven additional countries during the third quarter, bringing total international coverage to 32 nations. Global CF performance helped lift international revenue 16% to $1.27 billion. The company raised its full-year total revenue guidance to between $13.15 billion and $13.25 billion from a prior range of $13.1 billion to $13.2 billion. Alyftrek generated $705.8 million in third-quarter revenue, up from $247.0 million a year earlier. Vertex has also started global regulatory submissions for Alyftrek in children ages two to five.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment